Vietnam Diabetes Care Devices Market Overview, 2031

Key Insights

• A major structural transformation in the global diabetes care devices market is the expansion of Continuous Glucose Monitoring (CGM) systems into over-the-counter (OTC) consumer wearables. Historically limited to prescription-only Type 1 diabetes and intensive insulin-treated Type 2 populations, regulatory clearances for non-prescription biosensors (such as Dexcom’s Stelo and Abbott’s Lingo) have extended continuous glucose tracking to non-insulin Type 2 diabetics, prediabetics, and wellness-focused consumers. Strategic breakthroughs in this space center on 15-day factory-calibrated wear durations, low-profile form factors, needle-free or non-invasive optical/RF sensing innovation, and multi-analyte tracking capable of measuring glucose alongside lactate or ketones.
• The therapeutic landscape is rapidly shifting toward fully automated algorithmic ecosystem adoption. Next-generation closed-loop AID platforms (such as the Omnipod 5, Medtronic MiniMed 780G, and Tandem Control-IQ) continuously communicate with integrated CGMs (iCGMs) to automatically adjust basal insulin delivery every few minutes. Major technological breakthroughs include tubeless patch pumps, interoperable algorithm platforms (ACE pumps), smart connected insulin pen caps for multi-daily injection (MDI) regimens, and clinical milestones in fully implantable pump systems paired with temperature-stable insulin formulations.
• Over 42% of the individuals representing more than 250 million adults remain formally undiagnosed. Furthermore, over 540 million adults present with Impaired Fasting Glucose (IFG) or prediabetes. Global direct annual healthcare expenditures attributed to managing diabetes and its macrovascular and microvascular complications exceed $1 trillion USD, compelling healthcare systems worldwide to prioritize continuous tracking devices to prevent costly emergency room visits and chronic vascular organ damage.

Market Outlook

• The prospective landscape for diabetes devices is defined by hardware convergence with artificial intelligence (AI)-driven software and remote patient monitoring (RPM) platforms. Device manufacturers are moving beyond standalone hardware sales toward cloud-connected health portals that sync Ambulatory Glucose Profiles (AGP) and Time-in-Range (TIR) metrics directly into hospital Electronic Health Records (EHR) and nationwide tele-health systems.
• Key regulatory bodies, scientific associations, and patient advocacy organizations shaping global policy frameworks include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the International Diabetes Federation (IDF), the American Diabetes Association (ADA), and Breakthrough T1D (formerly JDRF). Leading commercial medical technology and diagnostic companies actively driving the global commercial marketplace include Abbott Laboratories, Dexcom, Inc., Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Roche Diabetes Care, Ypsomed AG, Ascensia Diabetes Care, and Senseonics Holdings.

Market Dynamics

Driver: Rising global diabetes prevalence
The primary growth driver for the global diabetes care devices market is the surging worldwide prevalence of diabetes paired with progressive reimbursement policies from public health authorities and private insurers. According to the International Diabetes Federation (IDF), over 589 million adults are living with diabetes globally, a number projected to climb significantly as sedentary lifestyles, urbanization, and aging populations accelerate chronic metabolic disease. To curb the staggering economic burden of long-term microvascular and macrovascular complications such as diabetic nephropathy, retinopathy, and cardiovascular disease governments and insurance bodies (such as Medicare/CMS in the US, statutory health funds across Europe, and national insurance systems in parts of Asia) are continuously expanding coverage frameworks.
Challenge: High cost barriers and global supply/procurement friction
Despite strong clinical demand, global market penetration is heavily constrained by high recurring device costs, restrictive reimbursement policies in emerging markets, and complex regulatory procurement frameworks. Advanced technologies such as continuous glucose sensors, smart transmitters, automated infusion pumps, and algorithm-driven closed-loop systems require ongoing, lifetime purchases of disposables (e.g., sensors, tubing, infusion sets, cartridges) that accumulate substantial annual expenses.
Trend: Expansion of over-the-counter (OTC) biosensors, AI software convergence, and smart pen ecosystems
A major trend reshaping the global diabetes care devices market is the transformation of continuous glucose monitors from prescription-bound medical equipment into over-the-counter (OTC) wearable biosensors, integrated with artificial intelligence (AI) and cloud health ecosystems. Following landmark clearances for non-prescription monitors, device manufacturers are rapidly targeting non-insulin Type 2 diabetics, prediabetics, and health-conscious consumer segments seeking real-time metabolic feedback. Parallel to hardware miniaturization, devices are increasingly converging with cloud analytics platforms, smart connected insulin pen caps for multiple daily injection (MDI) users, and mobile health software.

Segment Analysis

Diabetes Care Devices By Product Type
• The global blood glucose monitoring systems market is evolving from standalone testing devices toward connected solutions that support continuous diabetes management. Conventional glucometers remain important because of their accessibility, ease of operation, and usefulness for targeted glucose checks, while continuous glucose monitoring (CGM) systems provide a more detailed view of glucose fluctuations throughout the day. A key market differentiator is the ability to transform glucose readings into actionable insights through mobile applications, trend analysis, and remote data sharing with healthcare professionals. Manufacturers are increasingly challenged to balance sensor accuracy, wearable comfort, affordability, data privacy, and interoperability with digital health platforms.
• The insulin delivery devices market encompasses syringes, insulin pens, insulin pumps, smart pens, and automated insulin delivery systems. Product innovation is increasingly focused on simplifying dosing, improving delivery precision, and reducing the everyday burden of insulin therapy. Connected pens and pump systems can help users and clinicians review insulin administration alongside glucose trends, supporting more individualized treatment decisions. However, adoption depends on more than technical sophistication: device-specific consumable costs, compatibility, training requirements, and after-sales support all influence long-term usability.



Diabetes Care Devices By Disease Type
• The type 1 diabetes segment relies heavily on technologies that coordinate ongoing insulin administration with frequent glucose monitoring. CGM systems, insulin pumps, and automated insulin delivery solutions are important because they can help users respond to changing glucose levels and manage treatment throughout everyday activities. Product development increasingly emphasizes predictive alerts, customizable settings, discreet wearable designs, and data sharing with caregivers and healthcare professionals. Pediatric usability and support for school, exercise, travel, and changing daily schedules are also important considerations.
• The type 2 diabetes segment encompasses a broad range of monitoring needs because patients may manage their condition through lifestyle changes and oral medication or require insulin therapy. Conventional glucose meters remain useful for targeted testing, while CGM technologies can provide additional insight into glucose responses to meals, exercise, medication, and sleep for selected users. An important market opportunity lies in matching monitoring intensity to individual treatment needs rather than promoting the same device to every patient.

Diabetes Care Devices By End User
• The home and self-care segment is driven by the need for convenient, consistent diabetes management outside clinical settings. Patients use glucose meters, CGM systems, insulin pens, and pumps according to their treatment requirements and personal preferences. Smartphone connectivity and remote monitoring can help users share relevant information with clinicians and caregivers, while automated alerts may support timely responses to changing glucose levels. However, sustained adoption depends on practical factors such as affordability, comfort, ease of use, and reliable access to replacement supplies.
• Hospitals use diabetes care devices for inpatient glucose monitoring, insulin administration, treatment adjustment, and patient education. Their purchasing priorities include measurement reliability, clinical workflow compatibility, staff training, infection prevention, and dependable equipment servicing. Hospitals also influence the adoption of advanced technologies by introducing suitable patients to CGM systems and insulin pumps and helping them transition to home-based care. Integration with clinical information systems can make glucose trends easier for authorized healthcare teams to review, although interoperability and data security remain important considerations.
• Diagnostic centers contribute to diabetes screening, follow-up assessment, and evaluation of glycemic control through laboratory testing and related diagnostic services. Their priorities include standardized procedures, dependable equipment performance, quality assurance, efficient sample handling, and accurate reporting. Laboratory assessments complement personal glucose monitoring by providing clinicians with information that can be considered alongside readings collected during everyday activities.
• Ambulatory surgical centers require diabetes care devices that support appropriate glucose assessment and treatment coordination around outpatient procedures. Their priorities include reliable readings, rapid access to results, hygienic handling, and clear documentation for perioperative teams. Patients may arrive using personal glucose meters, CGM sensors, insulin pens, or insulin pumps, so staff need procedures for reviewing existing treatment and managing devices around surgery.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Diabetes Care Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Blood Glucose Monitoring Systems
• Insulin Delivery Devices

By Disease Type
• Type 1 Diabetes
• Type 2 Diabetes

By End User
• Home/Self-Care
• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers